|
© 2004 American Academy of Neurology B- and T-cell markers in opsoclonus–myoclonus syndromeImmunophenotyping of CSF lymphocytesFrom the Departments of Neurology (Dr. Pranzatelli, E. Tate and T. Allison), Pediatrics (Dr. Pranzatelli), Medical Microbiology and Immunology (Dr. Moticka, A. Travelstead), and Statistics and Research Consulting (Dr. Verhulst), Southern Illinois University School of Medicine, Springfield, Departments of Pediatrics and Neurology (Dr. Franz), University of Cincinnati, OH, Michigan Institute of Neurological Disorders (Dr. Nigro), Farmington Hills, Department of Neurology (Dr. Parke), University of Oklahoma College of Medicine, Oklahoma City, and Department of Neurology (Dr. Stumpf), Northwestern University, Evanston, IL. Address correspondence and reprint requests to Dr. M.R. Pranzatelli, National Pediatric Myoclonus Center, SIU School of Medicine, PO Box 19658, Springfield, IL 62794-9658; e-mail: mpranzatelli{at}siumed.edu Background: Although many lines of evidence suggest an autoimmune etiology, the pathophysiology of opsoclonus–myoclonus syndrome (OMS) remains poorly understood and no immunologic abnormalities have correlated with neurologic severity. Conventional immunotherapies often do not prevent relapse or permanent sequelae. Objective: To test the cellular immune hypothesis of OMS in a cross-sectional study and determine if CSF lymphocyte subset analysis provides biomarkers of disease activity. Methods: The expression of lymphocyte surface antigens was investigated in CSF and blood of 36 children with OMS and 18 control subjects, using a comprehensive panel of monoclonal antibodies to adhesion and activation proteins in combination with anti-CD3 and anti-CD45 antibodies in four-color fluorescence-activated cell sorting.
Results: Although most children with OMS had normal CSF cell counts, they exhibited expansion of CD19+ B-cell (up to 29%) and Conclusions: CSF B- and T-cell recruitment is linked to neurologic signs in pediatric OMS, which may relate to relapses and disease progression.
Received September 14, 2003. Accepted in final form March 2, 2004. Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the May 11 issue to find the title link for this article. See also page 1466 Presented at the 31st Annual Meeting of the Child Neurology Society, October 10 to 11, 2002, Washington, DC. This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
T-cell (up to 26%) subsets and a lower percentage of CD4+ T-cells and CD4/CD8 ratio, which persisted even years after disease onset and conventional treatments. The percentage of activated CSF T-cells was also higher. Abnormalities correlated with neurologic severity, as scored blinded from videotapes using a 12-item motor scale, and disease duration. No significant differences were found between tumor and no-tumor groups. In children with neuroblastoma, tumor resection or cancer chemotherapy did not alter immunologic abnormalities. 
